SYSTEMS MATRIX
Compare Four Evidence Chains
The same questions—what acts, what responds, what is measured, and how certain is the endpoint—applied across four unlike research subjects.
The short version
These four subjects belong together as examples, not substitutes. NAD+ is a cellular coenzyme whose precursors reliably affect a blood biomarker but have limited evidence for broad human benefits [1]. GHK-Cu is a copper-binding tripeptide with its strongest human evidence in small topical skin, penetration, and hair studies [8][10][12]. Semaglutide is a regulated GLP-1 receptor agonist supported by large randomized trials measuring weight, cardiovascular events, and kidney outcomes [14][15][16]. Thymosin alpha-1 is an immune-modulating peptide with mixed findings, including a large phase 3 sepsis trial that found no mortality benefit [18].
A useful comparison therefore asks where each evidence chain ends. Does it stop at chemistry, a cell response, a tissue measure, a biomarker, or a clinical endpoint? It also asks whether the evidence comes from isolated cells, animals, observational cohorts, small trials, or large randomized studies. This method prevents a dramatic molecular description from being mistaken for clinical proof and prevents one null result from being overextended into unrelated indications.
The multiscale matrix
| Subject | Molecular starting point | Cellular or tissue response | Human measure | Evidence boundary |
|---|---|---|---|---|
| NAD+ | Redox carrier; substrate for sirtuins, PARPs, and CD38 | Energy metabolism, DNA-response and signaling networks | Blood NAD+; selected metabolic and functional measures | Blood target engagement is clearer than durable tissue or clinical benefit [1] |
| GHK-Cu | Copper coordination by a tripeptide | Fibroblast and matrix programs; skin penetration and retention | Topical skin measures and a small combination hair trial | Small, formulation-sensitive studies; systemic use is not established [8][10][12] |
| Semaglutide | GLP-1 receptor agonism | Pancreatic, gastric, hypothalamic, cardiovascular, and renal pathways | Body weight and cardiovascular and kidney events | Strongest clinical endpoint program here, with defined safety limits [14][15][16][17] |
| Thymosin alpha-1 | TLR-linked immune modulation | Dendritic-cell, monocyte, and T-cell responses | Immune markers, infection outcomes, mortality | Mixed indication-specific evidence; phase 3 sepsis result was null [18] |
Mechanism is a map, not a verdict
NAD+ has the broadest claim to fundamental biology. Nearly every cell depends on its redox and signaling roles. That breadth makes causal attribution harder, not easier: changing an abundant cofactor may have different consequences across tissues, time, and disease states. GHK-Cu is spatially narrower. Its proposed actions concentrate at the extracellular matrix and tissue-repair interface, but the skin barrier and integrity of the copper complex constrain delivery.
Semaglutide begins with a pharmacologically defined receptor and a manufactured analogue designed to remain in circulation. Its pathway branches through the pancreas, gut, vagal signaling, and brain, then reaches measurable clinical outcomes. Thymosin alpha-1 acts in an adaptive network where direction matters: immune restoration, inflammatory control, and harmful activation cannot be reduced to one “stronger immunity” axis.
These differences explain why cross-compound rankings are not meaningful. A percentage change in blood NAD+ is not comparable with a percentage change in body weight. A skin-penetration measure is not comparable with mortality. The correct unit of comparison is the integrity of the chain from intervention to endpoint.
Evidence maturity and uncertainty
Semaglutide has the most mature clinical evidence in this set because thousands of participants were randomized in trials designed around clinical outcomes [14][15][16]. Mature does not mean complete: adverse effects, contraindications, long-term management, product quality, and population differences remain relevant [17].
NAD+ precursor research is intermediate. Randomized human studies show target engagement and some favorable secondary outcomes, but the latest synthesis emphasizes limited efficacy and sparse tissue data [1][2][3][5]. GHK-Cu combines deep mechanistic literature with a relatively thin and often small human trial base. Claims should remain close to topical delivery and measured outcomes [8][10][12].
Thymosin alpha-1 has substantial clinical history but heterogeneous evidence across conditions. The contrast between an encouraging earlier sepsis trial and the later null TESTS result shows how evidence maturity can revise a narrative [18][22]. Observational or retrospective findings may still motivate research, but randomization better controls the hidden differences that can shape outcomes [20].
A practical reading protocol
For any claim, identify five elements: the exact compound and formulation; the biological model or participant group; the route by which the intervention reached its target; the outcome measured; and the study design. Then ask whether the conclusion stays at that level.
A cell-study claim should sound like a cell-study claim. An animal mechanism should not become a human promise. A retrospective association should preserve uncertainty about confounding. A randomized outcome should report both its result and population. A null trial should be treated as information, not an inconvenience. Finally, approved pharmaceutical evidence should not be used to legitimize unregulated material with uncertain identity.
This protocol is the common architecture of Ascended Peptides. The individual pages provide depth, while the reference index makes the source trail inspectable.